CARGO Therapeutics is a technology company.
CARGO Therapeutics has raised $200.0M across 1 funding round.
Key people at CARGO Therapeutics.
CARGO Therapeutics has raised $200.0M in total across 1 funding round.
Key people at CARGO Therapeutics.
CARGO Therapeutics is a clinical-stage biotechnology company developing engineered cell therapies, specifically CAR T-cell therapies, aimed at providing potentially curative treatments for cancer patients.[1][2] It focuses on products like CRG-023, a tri-specific CAR T candidate in Phase 1 trials targeting three B-cell malignancies, and an allogeneic platform to reduce immune rejection for durable responses.[1] The company serves oncology patients, addressing unmet needs in cancer treatment by engineering more effective, off-the-shelf therapies; it went public in November 2023 with 167 employees and demonstrates growth through $591M in total funding.[1][2]
CARGO Therapeutics was incorporated in 2019 as Syncopation Life Sciences, Inc., rebranding to its current name in September 2022.[1] Some sources list a founding year of 2021, with headquarters in San Carlos or San Mateo, California.[1][2][3] Led by CEO Anup Radhakrishnan, the company emerged from efforts to advance CAR T-cell technologies, achieving early traction via multiple funding rounds totaling $591M, including a $110M recent raise, before its NASDAQ IPO (ticker: CRGX) on November 10, 2023, at $15 per share.[1][2] This pivot and public listing marked pivotal moments in scaling its clinical pipeline.
CARGO Therapeutics rides the wave of CAR T-cell therapy expansion, a key trend in immuno-oncology where engineered T-cells target cancers more precisely than traditional treatments.[1][2] Timing aligns with maturing allogeneic platforms, reducing manufacturing costs and patient wait times amid rising demand for scalable cancer cures—global CAR T markets are projected to grow as approvals increase for solid tumors and autoimmune uses. Market forces like FDA fast-tracking and investor interest in biotech IPOs (post-2023 listing) favor it, while its innovations influence the ecosystem by pushing tri-specific and rejection-resistant designs, potentially lowering barriers for broader adoption in healthcare.[1]
CARGO's Phase 1 data readouts for CRG-023 and allogeneic advancements will drive milestones, with trends like AI-optimized cell engineering and combo therapies shaping its path toward Phase 2/3 trials and partnerships.[1] Influence may evolve through expanded indications beyond B-cell malignancies, amplifying its role in accessible, curative oncology if rejection hurdles are cleared. This positions CARGO as a momentum player in biotech's cell therapy frontier, building on its public foundation for sustained impact.
CARGO Therapeutics has raised $200.0M in total across 1 funding round.
CARGO Therapeutics's investors include Third Rock Ventures.
CARGO Therapeutics has raised $200.0M across 1 funding round. Most recently, it raised $200.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $200.0M Series A | Third Rock Ventures |
